Goldfinch Bio Announces Appointment of Robin A. Walker (’99), JD, as Chief Legal Officer
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Robin A. Walker, JD, as Chief Legal Officer, effective immediately. Ms. Walker will be a member of the executive management team and lead the company’s legal organization, including its corporate governance and compliance functions.
“With Robin’s appointment, we continue to strengthen our corporate leadership and build out key functions to support the advancement of our pipeline of precision medicine product candidates for people living with severe and debilitating kidney diseases,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. “Robin brings to Goldfinch Bio deep knowledge of the biotechnology industry and a proven track record of building legal organizations within companies developing novel therapeutics for orphan and rare diseases. I believe her guidance will be critical as we continue to explore the full potential of our world-class product engine to uncover the genetic drivers of kidney disease and inform our growing clinical- and research-stage portfolio.”